Islam Md Torequl, Rahman Md Tahmidur, Mia Emon, Kamli Hossam, Hasan Ali Mohamod Wasaf, Uddin Mohammed Burhan, Sayeed Md Abu, Hasan Akayed, Emon Yasin, Yana Noshin Tasnim, Akter Mst Sumaia, Hossan Rakib, Al Hasan Md Sakib, Bhuia Md Shimul
Department of Pharmacy, Gopalganj Science and Technology University, Gopalganj, 8100, Bangladesh.
Bioinformatics and Drug Innovation Laboratory, BioLuster Research Center Ltd, Gopalganj, 8100, Bangladesh.
Med Oncol. 2025 Jun 26;42(8):285. doi: 10.1007/s12032-025-02839-6.
Daidzin (DZN), a naturally occurring isoflavone extracted from leguminous plants such as soybeans, has gained significant attention for its anticancer properties. This study provides a comprehensive overview of the pharmacokinetics (PKs), botanical sources, and therapeutic potentials of DZN, focusing on its mechanistic insights into cancer prevention and treatment. For the study, data were collected from databases such as PubMed, Google Scholar, Web of Science, and other reputable sources. In results, DZN induces oxidative stress, apoptosis, cytotoxicity, and cell cycle arrest while inhibiting proliferation, migration, invasion, and angiogenesis across various cancer cell lines, including breast, prostate, cervical, hepatocellular, and colon cancers. Its anticancer efficacy is mediated through modulation of key pathways: Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), which promotes inflammation and survival; Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT), essential for proliferation and immune evasion; and Rat Sarcoma virus/Rapidly Accelerated Fibrosarcoma (RAS/RAF), a critical regulator of cell growth and chemoresistance. By inhibiting these pathways, DZN enhances apoptosis and chemotherapy sensitivity. Additionally, DZN's pharmacokinetic profile reveals favorable absorption, distribution, metabolism, and excretion (ADME) properties, with minimal toxicity in preclinical studies. Its ability to modulate pathways and enhance chemotherapy sensitivity positions DZN as a potential therapeutic candidate. Despite promising preclinical findings, the lack of clinical validation underscores the need for well-designed human trials to confirm its efficacy and safety, paving the way for its translational application in oncology.
大豆苷（DZN）是一种从大豆等豆科植物中提取的天然异黄酮，因其抗癌特性而备受关注。本研究全面概述了DZN的药代动力学（PKs）、植物来源和治疗潜力，重点关注其在癌症预防和治疗方面的作用机制。在本研究中，数据收集自PubMed、谷歌学术、科学网等数据库以及其他可靠来源。结果显示，DZN可诱导氧化应激、细胞凋亡、细胞毒性和细胞周期停滞，同时抑制包括乳腺癌、前列腺癌、宫颈癌、肝细胞癌和结肠癌在内的多种癌细胞系的增殖、迁移、侵袭和血管生成。其抗癌功效是通过调节关键信号通路介导的：激活B细胞的核因子κB轻链增强子（NF-κB），该通路促进炎症反应和细胞存活；Janus激酶/信号转导子和转录激活子（JAK/STAT），这对细胞增殖和免疫逃逸至关重要；以及大鼠肉瘤病毒/快速加速纤维肉瘤（RAS/RAF），它是细胞生长和化疗耐药性的关键调节因子。通过抑制这些信号通路，DZN增强了细胞凋亡和化疗敏感性。此外，DZN的药代动力学特征显示出良好的吸收、分布、代谢和排泄（ADME）特性，在临床前研究中毒性极小。其调节信号通路和增强化疗敏感性的能力使DZN成为一种潜在的治疗候选药物。尽管临床前研究结果令人鼓舞，但缺乏临床验证凸显了开展精心设计的人体试验以确认其疗效和安全性的必要性，为其在肿瘤学中的转化应用铺平道路。
